Pasithea Therapeutics (NASDAQ:KTTA) Announces Earnings Results

Pasithea Therapeutics (NASDAQ:KTTA) announced its quarterly earnings results on Monday. The company reported ($2.41) EPS for the quarter, Zacks reports.

Pasithea Therapeutics Price Performance

KTTA traded up $0.01 during trading on Monday, reaching $1.25. 61,129 shares of the company were exchanged, compared to its average volume of 535,974. The firm has a 50 day moving average of $1.70 and a 200 day moving average of $2.97. Pasithea Therapeutics has a 52 week low of $0.92 and a 52 week high of $9.25.

About Pasithea Therapeutics

Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications.